Results 171 to 180 of about 155,199 (206)

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Lancet, The, 2021
Brad H Rovin, Cristina Arriens, Dawn J Caster   +2 more
exaly  

Cutaneous Lupus Erythematosus

2007
Thomas A. Luger, Gisela Bonsmann, Annegret Kuhn, Markus Böhm   +3 more
openaire   +1 more source

Cutaneous Lupus Erythematosus

Lillian Xie, Lais Lopes Almeida Gomes, Avery H. LaChance, Ruth Ann Vleugels, Katharina S. Shaw   +4 more
  +4 more sources

Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark

Lupus, 2018
M. P. Petersen, S. Moller, Anette Bygum, A. Voss, M. Bliddal   +4 more
semanticscholar   +1 more source

Systemic lupus erythematosus

Nature Reviews Disease Primers, 2016
Arvind Kaul, Caroline Gordon, Mary K Crow   +2 more
exaly  

Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis

Nature Reviews Nephrology, 2015
Chandra Mohan, Chaim Putterman
exaly  

The role of antimalarial agents in the treatment of SLE and lupus nephritis

Nature Reviews Nephrology, 2011
Earl D Silverman
exaly  

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease

Nature Medicine, 2016
Christian Lood, Luz P Blanco, Carmelo Carmona-Rivera   +2 more
exaly  

Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus

Lupus, 2018
H. Al-Rawi, S. Meggitt, F. Williams, S. Wahie   +3 more
semanticscholar   +1 more source

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Lancet, The, 2011
Sandra V Navarra, Ho-Youn Kim, Michelle A Petri   +2 more
exaly